The clinical outcomes of the AAVIATE study (NCT04514653) is discussed in this touchOPHTHALMOLOGY interview with Prof. Arshad Khanani (Sierra Eye Associates, Reno, NV, USA). RGX-314 is being developed as a potential one-time treatment for neovascular AMD as current anti-VEGF therapies require life-long intraocular injections to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.
The presentation entitled ‘Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022.
- What are the aims and methodology of the AAVIATE study?
- What have the initial findings taught us about the efficacy, safety and tolerability of RGX-314?
- Which patients are most likely to benefit from this treatment?
Disclosures: Arshad Khanani is a consultant for Regenxbio and discloses grant/research Support from Regenxbio.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Share this Video
Related Videos In Macular Degeneration
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Rahul Khurana, AAO 2022: Loss to follow-up in patients with nAMD treated with anti-VEGF therapy in the US
Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular degeneration. In this interview, he discusses with touchOPHTHALMOLOGY the design and findings of this study as […]
Francesco Bandello, EURETINA 2022: The Relationship Between OCTA and FA/ICGA in AMD Part 1
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) talks us through the advantages of optical coherence tomography angiography (OCTA) over conventional dye angiography in age-related macular degeneration (AMD) and a study investigating the relationship between OCTA and fluorescein angiography/indocyanine green angiography in AMD. ‘Morphological and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!